Skip to main content

Table 3 Pharmacological therapies for AE-IPF, currently proposed or under investigation

From: Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?

Therapy Study
Nintedanib (preventive therapy) Richeldi et al., 2011 [74]; Richeldi et al., 2014 [75]
Pirfenidone (preventative therapy) Azuma et al., 2005 [76]; Taniguchi et al., 2010 [77]
Anti-acid therapy (preventative therapy) Lee et al., 2013 [78]
Corticosteroid monotherapy Akira et al., 1997 [79]; Al-Hameed and Sharma, 2004 [80]; Suzuki et al., 2011 [81]; Tachikawa et al., 2012 [82]
Cyclophosphamide Akira et al., 2008 [83]; Fujimoto et al., 2012 [84]; Tachikawa et al., 2012 [82]; Yokoyama et al., 2010 [85]
Cyclosporine Homma et al., 2005 [86]; Inase et al., 2003 [87]; Sakamoto, et al., 2010 [88]; Fujimoto et al., 2012 [84]; Yokoyama et al., 2010 [85]
Polymyxin-B immobilized fiber column hemoperfusion Abe et al., 2011 [89]; Abe et al., 2012 [90]; Oishi et al., 2013 [91]; Seo et al., 2006 [92]; Tachibana et al., 2011 [93]
Rituximab, plasma exchange, and intravenous immunoglobulin Donahoe et al., 2015 [94]
Tacrolimus Horita et al., 2011 [95]
Thrombomodulin Kataoka et al., 2015 [96]; Tsushima et al., 2014 [97]; Isshiki et al., 2015 [98]
Cessation of immunosuppression, best supportive care, broad-spectrum antimicrobials: “nonsteroid approach” Papiris et al., 2015 [73]
  1. AE-IPF acute exacerbation of idiopathic pulmonary fibrosis